Sign in Subscribe

phase-ii

A collection of 4 issues

CRC Research Finding

Skip to content The CRC Digest ▸ Cell Therapy Shows Promise in Third-Line MSS Colorectal Cancer A phase 2B trial evaluated AlloStim®, an allogeneic activated memory Th1 cell therapy designed to convert "cold" tumors to "hot," in third-line MSS/pMMR metastatic colorectal cancer patients. (Translational Oncology) This

Shared decision-making training increases screening options

Skip to content The CRC Digest Shared decision-making training increases screening options A cluster randomized trial in Switzerland found that training primary care physicians in shared decision-making promoted offering both colonoscopy and FOBT for CRC screening. (PLoS One) This content is informational only and does not constitute medical advice. Always

ABFOLFOX neoadjuvant therapy studied in unresectable liver metastases

Skip to content The CRC Digest ◆ TRIAL DATA ABFOLFOX neoadjuvant therapy studied in unresectable liver metastases — Genome Medicine A study examined neoadjuvant ABFOLFOX (atezolizumab, bevacizumab, leucovorin, 5-fluorouracil, and oxaliplatin) in patients with unresectable colorectal liver metastases. The research explored molecular dynamics of tumor ecosystems and their impact on treatment outcomes.

Phase 2 trial tests fruquintinib plus chemotherapy in RAS-mutant CRC

Skip to content The CRC Digest ◆ TRIAL DATA Phase 2 trial tests fruquintinib plus chemotherapy in RAS-mutant CRC — Journal of Clinical Oncology A multicenter, open-label phase 2 study evaluated fruquintinib (a targeted therapy) combined with FOLFIRI or mFOLFOX6 chemotherapy as second-line treatment for patients with RAS-mutant metastatic colorectal cancer. RAS